Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
Globe Newswire•01/10/2026•09:20 ET
2
Key Highlights
- ➤ERNA-101 cleared tumors completely with 100% survival alongside anti-PD-1 in ovarian cancer model
- ➤IND submission targeted Q4 2026 for ERNA-101 in platinum-resistant ovarian cancer
- ➤First-in-human ERNA-101 study targeted Q1 2027 after clinical-grade manufacturing begins
- ➤Robert J. Spiegel appointed to Ernexa (ERNA) Board, adding oncology development and regulatory expertise
Expert Statements
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“We believe Ernexa is entering one of the most important periods in our evolution, and Dr. Spiegels’s addition to the Board comes at a highly relevant time.”
Sanjeev Luther, President and Chief Executive Officer of Ernexa Therapeutics
“His experience aligns directly with where we are headed as we move ERNA-101 toward the clinic. With meaningful development milestones ahead and a broader opportunity across difficult-to-treat solid tumors, we believe we are building a strong foundation for Ernexa’s next stage of growth.”
Robert J. Spiegel, Board member of Ernexa Therapeutics
“ERNA-101 represents a compelling approach to addressing some of the persistent challenges in ovarian cancer.”
Robert J. Spiegel, Board member of Ernexa Therapeutics
“I am encouraged by the progress Ernexa has made as ERNA-101 approaches clinical development and look forward to contributing my experience as the Company advances this program and its broader oncology strategy.”
CEO Discusses How Addition of Accomplished Oncology Drug Developer Strengthens Ernexa Ahead of Clinical Development Following ERNA-101 Data Demonstrating Complete Tumor Clearance and 100% Survival in Combination with anti-PD-1
Discussion Highlights ERNA-101’s Near-Term Milestones and Broader Potential Across Difficult-to-Treat Solid Tumors
Get started
Create a free account to read the full story.